National Advisory Committee on Immunization (NACI) recommends RSV immunization programs use nirsevimab to prevent severe RSV disease. Programs can build and expand over time depending on access to supply, cost-effectiveness, and affordability of available options (STRONG RECOMMENDATION[†]).[1]

When RSV season is here, Beyfortus® is at hand[2-4]

Introducing an antibody indicated for the prevention of RSV lower respiratory tract disease in infants during their first season[2*]

Beyfortus® (nirsevimab)

Beyfortus® may be publicly funded in your province or territory (with criteria). Please refer to your local public health unit for further information.

For more information on Beyfortus®, scan the QR code.

Beyfortus® is indicated for the prevention of RSV lower respiratory tract disease in:

- Neonates and infants during their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, which may include but is not limited to children with:
  - Chronic lung disease of prematurity (CLD)
  - Hemodynamically significant congenital heart disease (CHD)
  - Immunocompromised states
  - Down syndrome
  - Cystic fibrosis
  - Neuromuscular disease
  - Congenital airway anomalies.

sanofi

Consult the product monograph at https://www.sanofi.com/assets/countries/canada/docs/products/vaccines/beyfortus-en.pdf for contraindications, warnings, precautions, adverse reactions, interactions, dosing, and conditions of clinical use. The product monograph is also available through our medical department. Call us at 1-800-265-7927.

RSV=respiratory syncytial virus.
Sanofi & AstraZeneca are collaborating on the development and commercialization of Beyfortus®.
* Beyfortus® is a human monoclonal antibody.[2]
† Strong recommendation applies to most populations/individuals and should be followed unless a clear and compelling rationale for an alternative approach is present.

References: 1. An Advisory Committee Statement (ACS)/National Advisory Committee on Immunization (NACI): Statement on the prevention of respiratory syncytial virus (RSV) disease in infants. May 17, 2024. **2.** Beyfortus® Product Monograph, June 16, 2024. **3.** Bianchini S, et al. *Microorganisms* 2020;8:2048. doi: 10.3390/microorganisms8122048. **4.** Pisesky A, et al. *PLoS One* 2016;11(3):e0150416. doi: 10.1371/journal.pone.0150416.

© 2024 Sanofi Pasteur Limited. All rights reserved.
MAT-CA-2400970E-v1.0-09/2024

Please do not use this piece after 31/08/2026 as some of the information may be outdated.

MEMBER OF INNOVATIVE MEDICINES CANADA